Syndax Pharmaceuticals Inc (NASDAQ: SNDX) is -38.41% lower on its value in year-to-date trading and has touched a low of $12.75 and a high of $25.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SNDX stock was last observed hovering at around $13.08 in the last trading session, with the day’s gains setting it 0.23%.
Currently trading at $13.31, the stock is -12.01% and -22.77% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.8 million and changing 1.76% at the moment leaves the stock -33.32% off its SMA200. SNDX registered -33.95% loss for a year compared to 6-month loss of -31.88%. The firm has a 50-day simple moving average (SMA 50) of $17.3502 and a 200-day simple moving average (SMA200) of $20.01745.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -14.68% gain in the last 1 month and extending the period to 3 months gives it a -27.19%, and is -3.48% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.63% over the week and 5.33% over the month.
Syndax Pharmaceuticals Inc (SNDX) has around 184 employees, a market worth around $1.14B and $16.00M in sales. Profit margin for the company is -1856.64%. Distance from 52-week low is 4.39% and -47.47% from its 52-week high. The company has generated returns on investments over the last 12 months (-81.07%).
with sales reaching $115.89M over the same period.The EPS is expected to shrink by -22.00% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Syndax Pharmaceuticals Inc (SNDX) Top Institutional Holders
296.0 institutions hold shares in Syndax Pharmaceuticals Inc (SNDX), with institutional investors hold 107.37% of the company’s shares. The shares outstanding are 85.57M, and float is at 81.08M with Short Float at 17.76%. Institutions hold 106.50% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.91 million shares valued at $162.33 million. The investor’s holdings represent 9.2788% of the SNDX Shares outstanding. As of 2024-06-30, the second largest holder is WELLINGTON MANAGEMENT GROUP LLP with 7.34 million shares valued at $150.67 million to account for 8.6125 of the shares outstanding. The other top investors are KYNAM CAPITAL MANAGEMENT, LP which holds 5.72 million shares representing 6.715% and valued at over $117.47 million, while VANGUARD GROUP INC holds 5.6295 of the shares totaling 4.8 million with a market value of $98.48 million.
Syndax Pharmaceuticals Inc (SNDX) Insider Activity
The most recent transaction is an insider purchase by Goldan Keith A., the company’s Chief Financial Officer. SEC filings show that Goldan Keith A. bought 1,250 shares of the company’s common stock on Jun 14 ’24 at a price of $20.03 per share for a total of $25037.0. Following the purchase, the insider now owns 52623.0 shares.
